Sickle cell disease (SCD) is a common, life-threatening genetic disorder that is best managed when diagnosed early by newborn screening. However, SCD is most prevalent in low-resource regions of the world where newborn screening is rare and diagnosis at the point-of-care is challenging. In many such regions, the majority of affected children die, undiagnosed, before the age of 5 years. A rapid and affordable point-of-care test for SCD is needed. The diagnostic accuracy of HemoTypeSC, a point-of-care immunoassay, for SCD was evaluated in individuals who had SCD, hemoglobin C disease, the related carrier (trait) states, or a normal hemoglobin phenotype.
| INTRODUCTION
Sickle cell disease (SCD) is a group of genetic blood disorders caused by sickle hemoglobin (HbS; HBB:c.20A>T[p.E7V]) and characterized by acute and chronic multiorgan damage and dysfunction due to vaso-occlusion and hemolysis. Manifestations of SCD include painful episodes, cardiopulmonary disease, stroke, nephropathy, susceptibility to invasive bacterial infections, and early mortality. 1, 2 In many highresource regions, universal newborn screening programs coupled with prophylactic interventions have dramatically reduced the mortality and morbidity of SCD during the first 20 years of life. [3] [4] [5] [6] [7] [8] However, in sub-Saharan Africa and central India, where > 90% of annual SCD births occur, newborn screening programs have not been implemented universally, if at all, due in large part to the cost and logistical burden of laboratory diagnostic tests. 9 Up to 90% of children with SCD in sub-Saharan Africa are thought to die before the age of 5 years, undiagnosed, 10 making SCD one of the leading causes of childhood mortality in the region. [11] [12] [13] Individuals with SCD in these regions are commonly identified only after hospitalization for severe pain or other overt or life-threatening manifestation of the disease. Its effects on mortality and quality of life and its economic burden on regional healthcare systems have led SCD to be declared both a disease of public concern by the United Nations General Assembly 14 and a priority noncommunicable disease by World Health Organization. 15 Early diagnosis and intervention programs for SCD are projected to be cost-effective in sub-Saharan Africa and India, 16, 17 and the World Health Organization estimates that such programs would prevent 70% of existing SCD mortality. 18 However, the main barriers to implementing newborn screening programs at scale include the cost of diagnostic methods, lack of adequately distributed laboratory infrastructure, and lack of adequate, sustained funding. Standard clinical laboratory methods to identify Hb variants include gel-based or capillary electrophoresis, isoelectric focusing (IEF), and high-performance liquid chromatography (HPLC). These methods require about 1 mL of whole blood, uninterrupted electrical supply, dedicated operating personnel, and necessitate the transport of blood samples from the point-of-care (POC) to possibly distant testing facilities. 19 Furthermore, these methods require the recontacting of affected newborns' families in order to deliver testing results-sometimes weeks or months after sample collection. It is clear that a rapid, inexpensive, and highly-accurate POC solution for SCD diagnosis is urgently needed.
Several rapid diagnostic methods have been described for SCD.
The sickle cell solubility test (Sickledex) 20 can rapidly identify the presence of HbS in a blood sample, but it does not distinguish between sickle cell trait and SCD. Furthermore, this test is not reliable when HbS levels are below 15%-20%, so it is not suited for newborn screening. A variation of the sickle cell solubility test has been reported to distinguish HbA/S and HbS/S from HbA/A phenotypes through visualization of differential diffusion patterns on filter paper in the presence of a solubility buffer. 21 However, these diffusion patterns may be difficult to distinguish, and a computer and scanner are required for optimal visualization. Recently, a lateral flow immunoassay called Sickle SCAN has been described, which is capable of distinguishing HbA-, HbS-, and HbC-related phenotypes in a large drop of blood (5 μL). 22 Sickle SCAN has a very high limit of detection for HbA HemoTypeSC is a competitive lateral-flow immunoassay that uses monoclonal antibodies to detect hemoglobins A, S, and C in a 1. 
| Study populations
At Holy Family Hospital in Techiman, Ghana (low-resource), newborns, children, and adult family members were enrolled from the ambulatory pediatric clinic and neonatal intensive care unit, and also adult hospital staff. At the study center in Martinique (medium- 
| Study procedure
From each participant, a 1.5-μL sample of blood was first collected for the HemoTypeSC test using the provided blood collection device from a heel-prick (newborns, infants, and small children) or venipuncture (older children and adults). A larger blood sample was obtained in a collection tube for confirmatory analysis. In Ghana and Martinique,
HemoTypeSC testing was performed immediately upon sample collection from each participant, while at the USA study center, blood was transported to a diagnostic laboratory where aliquots were used for 
| HemoTypeSC test procedure
The HemoTypeSC test kit (included components, testing procedure, and interpretation guidelines) is illustrated in Supporting Information Figure S1 . Operators were trained to use the device by reading the test instruction sheet (Supporting Information Figure S1 ) that describes the following 5 steps. First, using the included dropper pipette, 6 drops of water were dispensed into a test tube. Bottled drinking water was used at the Ghana and Martinique study sites; tap water was used at the US site. Second, a 1.5-μL blood droplet was collected with the included blood collection device. Third, the blood collection device was inserted into the water within the test tube and swirled to ensure blood transfer from the absorbent pad of the blood collection device into the water. Fourth, the test strip was inserted into the water-blood mixture within the test tube. Finally, the result on the test strip was interpreted visually after 10 minutes.
| Confirmatory laboratory procedures
In Ghana and Martinique, agarose gel electrophoresis and IEF were performed according to standard clinical laboratory protocols. In the USA, screening capillary zone electrophoresis was performed on was performed on a VARIANT II Instrumentation System (Bio-Rad, USA) for discordant samples only.
| Analysis
The primary objective was to determine the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of 3 | RESULTS
| Study participants
A total of 608 participants registered for the study, including 402 from Ghana (low-resource), 46 from Martinique (medium-resource), and 160 from the USA (high-resource; Figure 1 ). A total of 18 participants from the Ghana study center and 2 participants from the USA study center provided insufficient blood for testing by a confirmatory method and were excluded prior to analysis. Thus, 588 participants were included in the study. One specimen from the Ghana study group subsequently produced indeterminate confirmatory method results and was ruled ineligible for data analysis. Therefore, 587 participants comprised the main analysis population (Figure 1 ). Both sexes and a wide range of ages (newborn to age 30 years) were represented ( 
| Analysis by Hb variant
The HemoTypeSC test combines independent competitive immunoassays for each of 3 Hb variants (HbA, HbS, and HbC). Therefore, the sensitivity and specificity of HemoTypeSC were first calculated for the detection of each particular Hb ( Newborns, children, and adults were registered for the study from low-(Ghana), medium-(Martinique), and high-resource testing environments. A total of 20 participants (mostly very small newborns) were initially excluded from the study due to the lack of adequate collected blood volume for confirmatory testing. Ultimately, 588 individuals were enrolled in the study, and Hb screening was conducted by comparing HemoTypeSC to 3 separate, clinically established reference methods (agarose gel electrophoresis, IEF, and capillary zone electrophoresis). Following a final exclusion of one specimen producing indeterminate reference method results, a total of 383 results from Ghana, 46 results from Martinique, and 158 results from the USA (total n = 587) comprised the main analysis population 
| Discordant results
In total, 4 of 587 total specimens (<1%) yielded discordant results between HemoTypeSC and the reference method (Supporting Information Table S1 ). The first discordant specimen yielded a HemoTypeSC/agarose electrophoresis phenotype discrepancy of HbAC/ HbAA. HPLC confirmed the HbAC HemoTypeSC result. Therefore, this result was included in the detection analysis by Hb variant (Table 2 ) as a true positive for both HbA and HbC and in the detection analysis by phenotype (Table 3) 
| Samples with insufficient blood sample volume
There were 18 participants from Ghana who were registered for the study but unable to provide sufficient blood by venipuncture for confirmatory testing by agarose gel electrophoresis. All of these specimens came from premature newborns, from whom only a few drops of blood could be feasibly collected (dried blood spot testing was not a standard practice at this testing center). HemoTypeSC testing could, however, still be conducted on these samples, and results included 13 HbAA, 2 HbAS, 2 HbAC, and 1 HbSC. Because confirmatory testing was not conducted, these participants were excluded from the main analysis population.
| DISCUSSION
In this international, multi-center study, HemoTypeSC exhibited >99% sensitivity and specificity for detection of each of 3 Hb types, HbA, HbS, and HbC, and > 99% sensitivity and specificity for each relevant 
